Vivace Therapeutics presents new preclinical data demonstrating strong synergistic activity for the combination of VT3989 and osimertinib at the 2022 American Association for Cancer Research (AACR) Annual Meeting

0

Combination Treatment Demonstrates Increased Efficacy and Delayed Tumor Growth Compared to Osimertinib Alone in EGFR Mutant Non-Small Cell Lung Cancer Models

VT3989, a first-in-class TEAD autopalmitoylation inhibitor currently being evaluated in Phase 1 clinical trials

SAN MATEO, Calif. , April 11, 2022 /PRNewswire/ — Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, today announced that new preclinical data on the autopalmitoylation inhibitor of the company’s enhanced transcriptional associated domain (TEAD), VT3989, were reported at the 2022 American Association for Cancer Research (AACR) Annual Meeting. The results presented demonstrated that the combination of VT3989 and osimertinib (Tagrisso®), an epidermal growth factor receptor (EGFR) inhibitor, possessed enhanced anti-tumor activity and delayed tumor growth compared to osimertinib alone in preclinical EGFR mutant tumor models. AACR conference is held April 8-13, 2022in New Orleans, Louisiana.

The data reported in the poster presentation demonstrated that VT3989 exhibits strong synergistic activity with osimertinib. This was evidenced by the combination’s ability to enhance tumor growth blockade in xenograft models derived from EGFR mutant non-small cell lung cancer (NSCLC) cell lines, including the HCC827 model which is already known to be particularly sensitive to osimertinib. Additionally, the combination of VT3989 and osimertinib significantly increased the lifespan of mice in an NCI-H1975 NSCLC CDX model compared to osimertinib monotherapy.

Additionally, the researchers showed similar synergistic activity in blocking tumor regrowth in xenograft models derived from human EGFR mutant NSCLC patients. Of note, the data demonstrated that TEAD inhibition achieved with VT3989 significantly delayed reemergence of tumor mass after osimertinib treatment resulted in nonpalpable tumors. This finding offers evidence that the EGFR mutant NSCLC relies on a dysfunction of the Hippo pathway to survive treatment with osimertinib, and therefore may be targeted by TEAD inhibition.

“The exciting new data presented at the AACR not only supports previous research highlighting the potency and selectivity of VT3989 as a TEAD inhibitor and its single-agent antitumor activity in mesothelioma models, but the results are beginning to also to build a compelling strategy around a synergistic combination treatment approach featuring VT3989 and EGFR inhibitors such as osimertinib,” said Tracy Tang, Ph.D., Vice President of Biology at Vivace Therapeutics and senior author of the AACR poster presentation. “We look forward to continuing our pioneering research into the Hippo pathway and how addressing dysfunctions in this pathway can pave the way for first-class cancer therapies that can address unmet patient needs.”

Vivace’s proprietary compounds inhibit the palmitoylation of members of the TEAD protein family, including covalent and non-covalent inhibitors. The Company’s clinical candidate, VT3989, is currently in Phase 1 clinical trials. Preclinical research and development activities have demonstrated that the clinical candidate is active as a monotherapy against tumors that are dependent on Hippo pathway dysfunction, and in combination with other cancer therapies in other tumor types.

The featured poster is available on the company’s website www.vivacetherapeutics.com.

About Vivace Therapeutics, Inc.
Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. The company is pursuing a cutting-edge approach to treating human carcinomas with significant unmet medical needs. Situated at San Francisco Bay Areathe company raised $70 million to date, and is backed by leading biotech investors including Canaan Partners, WuXi Healthcare Ventures, Cenova Capital, Sequoia Capital China, Boxer Capital and RA Capital Management. For more information, please visit www.vivacetherapeutics.com.

Tagrisso® is a registered trademark of the AstraZeneca group of companies.

Contact information

Sofie Qiaodoctorate
President and CEO
info@vivacetherapeutics.com
650.666.2753

Tim Bron
Vida strategic partners (media)
646-319-8981
tbrons@vidasp.com

Quote

View original content: https://www.prnewswire.com/news-releases/vivace-therapeutics-presents-new-preclinical-data-highlighting-strong-synergistic-activity-for-combination-of-vt3989-and-osimertinib – at-american-association-for-cancer-research-aacr-annual-meeting-2022-301520268.html

SOURCE Vivace Therapeutics, Inc.

Share.

About Author

Comments are closed.